drugset / Trial / NCT00518739
MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK2461 | Small molecule | 60 mg | Oral |
| Subject | MK2461 | Small molecule | 240 mg | Oral |